Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients
Translational Oncology, 2020 Ovarian cancer (OC) is an important cause of gynecologic cancer-related deaths. In Mexico, around 4700 new cases of OC are diagnosed per year and it represents the second cause of gynecological cancer mortality with more than 2700 deaths.
Dolores Gallardo-Rincón +11 more
doaj +1 more source
Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model [PDF]
, 2012 Ovarian cancer is the leading cause of cancer related deaths in women. Genetic alterations including overexpression of EGFR play a crucial role in ovarian carcinogenesis.
Joseph Alan Bauer +4 more
core +3 more sources
Current Oncology, 2022 Prior to 1997, ovarian cancer (OC) was a ‘poor target’ for patient advocacy. At that time, there were only three OC researchers in Canada, little information available for women diagnosed, and no community of survivors existed.
Elisabeth Baugh +4 more
doaj +1 more source
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
New England Journal of Medicine, 2018 BACKGROUND Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum‐based chemotherapy.
K. Moore +20 more
semanticscholar +1 more source
npj Precision Oncology, 2021 Endometrioid ovarian carcinoma (EnOC) is an under-investigated ovarian cancer type. Recent studies have described disease subtypes defined by genomics and hormone receptor expression patterns; here, we determine the relationship between these subtyping ...
Robert L. Hollis +12 more
doaj +1 more source
Ovarian and cervical cancer awareness: development of two validated measurement tools. [PDF]
, 2011 The aim of the study was to develop and validate measures of awareness of symptoms and risk factors for ovarian and cervical cancer (Ovarian and Cervical Cancer Awareness Measures)
Corker, E +7 more
core +2 more sources
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
New England Journal of Medicine, 2019 BACKGROUND Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent ovarian cancer after platinum-based chemotherapy ...
A. González-Martín +29 more
semanticscholar +1 more source
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. [PDF]
, 2013 PurposeMET alterations including amplifications and nucleotide variations have been associated with resistance to therapy and aggressive clinical behavior.Experimental designThe medical records of patients presenting to the University of Texas MD ...
De Melo Galgiato, Debora +13 more
core +9 more sources
DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance
Neoplasia: An International Journal for Oncology Research, 2011 Clinical resistance to chemotherapy is a frequent event in cancer treatment and is closely linked to poor outcome. High-grade serous (HGS) ovarian cancer is characterized by p53 mutation and high levels of genomic instability. Treatment includes platinum-
Euan A. Stronach +6 more
doaj +1 more source
MS: Wip1 suppresses angiogenesis through the STAT3-VEGF signalling pathway in serous ovarian cancer
Journal of Ovarian Research, 2022 Multifaceted functions of the so-called “oncogene” Wip1 have been reported in a previous study, while its actual role remains to be explored in serous ovarian cancer (SOC).
Sheng Yin +3 more
doaj +1 more source